Lupin has launched Loteprednol Etabonate Ophthalmic Suspension, 0.5%, in the United States (U.S.). Loteprednol Etabonate Ophthalmic Suspension, 0.5% is bioequivalent to Lotemax Ophthalmic Suspension, 0.5%, of Bausch & Lomb Inc. 

Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. 

It is also indicated for the treatment of post-operative inflammation following ocular surgery. Loteprednol Etabonate Ophthalmic Suspension (RLD Lotemax) had estimated annual sales of $55 million in the U.S. (IQVIA MAT May 2025).

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.